Safety and efficacy of an all-oral interferon-free regimen of seraprevir, an NS3/4A protease inhibitor and sofosbuvir in patients with chronic hepatitis C virus (HCV) genotype 1: an open-label, multicentre, phase 3 trial

被引：0

作者：

Wen, Xiaoyu ^{[1
]}

Kong, Fei ^{[1
]}

Wen, Xiaofeng ^{[2
]}

Wang, Xiaozhong ^{[3
]}

Lin, Shide ^{[4
]}

Wu, Guicheng ^{[5
]}

Wang, Li ^{[6
]}

Xing, Huichun ^{[7
]}

Yan, Xuebing ^{[8
]}

Zheng, Sujun ^{[9
]}

Ning, Qin ^{[10
]}

Wang, Zheng ^{[11
]}

Zhang, Liaoyun ^{[12
]}

Li, Jianmei ^{[13
]}

Tong, Zhaowei ^{[14
]}

Su, Minghua ^{[15
]}

Tong, Lixin ^{[16
]}

Huang, Chengyu ^{[17
]}

Jia, Ji-Dong ^{[18
]}

Xin, Yongning ^{[19
]}

Zhu, Qingjing ^{[20
]}

Wang, Jing ^{[21
]}

Zhang, Yuexin ^{[22
]}

Li, Guangming ^{[23
]}

Niu, Junqi ^{[1
]}

机构：

[1] First Hosp Jilin Univ, Hepatol, Changchun, Peoples R China

[2] Liuzhou Peoples Hosp, Liuzhou, Peoples R China

[3] Xinjiang Uygur Autonomous Reg Tradit Chinese Med, Tibetan, Peoples R China

[4] Zunyi Med Coll, Affiliated Hosp, Zunyi, Guizhou, Peoples R China

[5] Chongqing Three Gorges Cent Hosp, Chongqing, Peoples R China

[6] Chengdu Publ Clin Hlth & Med Ctr, Chengdu, Peoples R China

[7] Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China

[8] Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China

[9] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China

[10] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China

[11] Fifth Hosp Wuxi, Wuxi, Jiangsu, Peoples R China

[12] Shanxi Med Univ, Hosp 1, Jinzhong, Peoples R China

[13] Sichuan Prov Peoples Hosp, Chengdu, Peoples R China

[14] Huzhou City Cent Hosp, Huzhou, Peoples R China

[15] Guangxi Med Univ, Hosp 1, Nanning, Peoples R China

[16] Hebei Med Univ, Hosp 1, Shijiazhuang, Hebei, Peoples R China

[17] Chongqing Publ Clin Hlth & Med Ctr, Chongqing, Peoples R China

[18] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[19] Qingdao City Cent Hosp, Qingdao, Peoples R China

[20] Jinyintan Hosp Wuhan, Wuhan, Peoples R China

[21] Southwest Med Univ, Tradit Chinese Med Hosp, Luzhou, Peoples R China

[22] Xinjiang Med Univ, Hosp 1, Urumqi, Peoples R China

[23] Zhengzhou Sixth Peoples Hosp, Zhengzhou, Peoples R China

来源：

JOURNAL OF HEPATOLOGY | 2020年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

THU391

引用

页码：S330 / S330

页数：1

共 50 条

[21] ACCELERATED CLINICAL TRIAL DESIGN TO ASSESS THE SAFETY, TOLERABILITY AND ANTI-VIRAL ACTIVITY OF PHX1766, A NOVEL HCV NS3/4A PROTEASE INHIBITOR, IN HEALTHY VOLUNTEERS AND CHRONIC HEPATITIS C PATIENTS
Hotho, Daphne
de Bruijne, Joep
O'Farrell, Anne-Marie
Boyea, Teresa
Li, Jack
Weegink, Christine J.
Schinkel, Janke
Molenkamp, Richard
van de Wetering, Jeroen
van Vliet, Andre A.
Janssen, Harry L.
de Knegt, Robert J.
Reesink, Hendrik W.
HEPATOLOGY, 2009, 50 (04) : 1031A - 1032A
[22] SOUND-C2: SVR4, 12, and 24 concordance in genotype (GT) 1 HCV patients receiving interferon (IFN)-free treatment with the HCV NS3/4A protease inhibitor BI 201335 and the NS5B polymerase inhibitor BI 207127
Zeuzem, Stefan
Soriano, Vincent
Asselah, Tarik
Bronowicki, Jean-Pierre
Lohse, Ansgar W.
Mullhaupt, Beat
Schuchmann, Marcus
Bourliere, Marc
Buti, Maria
Roberts, Stuart K.
Gone, Edward J.
Stern, Jerry O.
Vinisko, Richard
Herichova, Ivona
Boecher, Wulf O.
Mensa, Federico J.
HEPATOLOGY, 2012, 56 : 569A - 569A
[23] Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies
Berger, K. L.
Scherer, J.
Ranga, M.
Sha, N.
Stern, J. O.
Quinson, A. -M.
Kukolj, G.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (10) : 6017 - 6025
[24] MK-5172, a Novel Macrocyclic Inhibitor of NS3/4a Protease Demonstrates Efficacy Against Viral Resistance in the Chimpanzee Model of Chronic Hepatitis C Virus Infection
Ludmerer, Steve
Carroll, Steve
McCauley, John
Rudd, Mike
Coleman, Paul
Liverton, Nigel
Burlein, Christine
DiMuzio, Jill
Gates, Adam
Graham, Don
McHale, Carolyn
Stahlhut, Mark
Fandozzi, Christine
Hazuda, Daria
Vacca, Joe
Olsen, David
ANTIVIRAL RESEARCH, 2010, 86 (01) : A21 - A21
[25] Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study
Lawitz, Eric
Landis, Charles S.
Flamm, Steven L.
Bonacini, Maurizio
Ortiz-Lasanta, Grisell
Huang, Jonathan
Zhang, Jie
Kirby, Brian J.
De-Oertel, Shampa
Hyland, Robert H.
Osinusi, Anu O.
Brainard, Diana M.
Robson, Richard
Maliakkal, Benedict J.
Gordon, Stuart C.
Gane, Edward J.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (10): : 918 - 926
[26] A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients
Lawitz, Eric J.
Hill, John M.
Marbury, Thomas
DeMicco, Michael P.
Delaney, William
Yang, Jenny
Moorehead, Lisa
Mathias, Anita
Mo, Hongmei
McHutchison, John G.
Rodriguez-Torres, Maribel
Gordon, Stuart C.
ANTIVIRAL THERAPY, 2013, 18 (03) : 311 - 319
[27] Safety and Efficacy of Ledipasvir/Sofosbuvir Single-Tablet-Regimen in African Americans with Genotype 1 Chronic Hepatitis C Virus: A Retrospective Analysis of Phase 3 Studies
Jeffers, Lennox J.
Wilder, Julius M.
Muir, Andrew J.
Howell, Charles
Zhu, Yanni
Seyedkazemi, Star
Yang, Jenny C.
Pang, Phillip S.
McHutchison, John G.
Reddy, K. Rajender
HEPATOLOGY, 2014, 60 : 319A - 320A
[28] In vitro synergistic antiviral activity of ITMN-191, an orally active inhibitor of the hepatitis C virus (HCV) NS3/4A protease, in combination with PEG-Interferon alfa-2A
Tan, Hua
Seiwert, Scott D.
Blatt, Lawrence M.
HEPATOLOGY, 2006, 44 (04) : 534A - 534A
[29] Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
Kowdley, Kris V.
Lawitz, Eric
Crespo, Israel
Hassanein, Tarek
Davis, Mitchell N.
DeMicco, Michael
Bernstein, David E.
Afdhal, Nezam
Vierling, John M.
Gordon, Stuart C.
Anderson, Jane K.
Hyland, Robert H.
Dvory-Sobol, Hadas
An, Di
Hindes, Robert G.
Albanis, Efsevia
Symonds, William T.
Berrey, M. Michelle
Nelson, David R.
Jacobson, Ira M.
LANCET, 2013, 381 (9883): : 2100 - 2107
[30] Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial (vol 16, pg 685, 2016)
Manns, M.
Samuel, D.
Gane, E. J.
LANCET INFECTIOUS DISEASES, 2016, 16 (06): : 636 - 636

← 1 2 3 4 5 →